SHANGHAI – Innovent Biologics Inc., of Suzhou, has kicked off two pivotal phase III trials in China for biosimilar antibodies of global blockbusters. Innovent's IBI301 will be tested in a head-to-head trial with Rituxan/Mabthera (rituximab, Roche AG) in patients with non-Hodgkin lymphoma and IBI303 will go up against Humira (adalimumab, Amgen Inc.) for the treatment of ankylosing spondylitis.